These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1626555)

  • 1. Impact of reimbursement regulations on patient management.
    Hull AR
    Am J Kidney Dis; 1992 Jul; 20(1 Suppl 1):8-11. PubMed ID: 1626555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should the medicare ESRD program pay for daily dialysis? An ethical analysis.
    Anantharaman P; Moss AH
    Adv Chronic Kidney Dis; 2007 Jul; 14(3):290-6. PubMed ID: 17603984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The direction of end-stage renal disease reimbursement in the United States.
    Lockridge RS
    Semin Dial; 2004; 17(2):125-30. PubMed ID: 15043614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The costs of dialysis in the USA.
    Garella S
    Nephrol Dial Transplant; 1997; 12 Suppl 1():10-21. PubMed ID: 9075223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of end stage renal disease and implications for public policy.
    Rubin RJ
    Public Health Rep; 1984; 99(5):492-8. PubMed ID: 6435162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The end-stage renal disease program: trends over the past 18 years.
    Port FK
    Am J Kidney Dis; 1992 Jul; 20(1 Suppl 1):3-7. PubMed ID: 1626554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-quality trade-offs in dialysis care: a national survey of dialysis facility administrators.
    Powe NR; Thamer M; Hwang W; Fink NE; Bass EB; Sadler JH; Levin NW
    Am J Kidney Dis; 2002 Jan; 39(1):116-26. PubMed ID: 11774110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Projected impact of the proposed "bundled" ESRD payment system on a small dialysis organization.
    Bhat P; Sokolowski W; Bhat JG
    Nephrol News Issues; 2009 Jun; 23(7):46, 48-52. PubMed ID: 19585810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How dialysis is paid for: what the dialysis medical director should know, and why.
    Deoreo PB
    Semin Dial; 2008; 21(1):58-62. PubMed ID: 18086259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The financial implications for Medicare of greater use of peritoneal dialysis.
    Neil N; Guest S; Wong L; Inglese G; Bhattacharyya SK; Gehr T; Walker DR; Golper T
    Clin Ther; 2009 Apr; 31(4):880-8. PubMed ID: 19446160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A quarter century of medicare expenditures for ESRD.
    Eggers PW
    Semin Nephrol; 2000 Nov; 20(6):516-22. PubMed ID: 11111852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The legislative and regulatory process in the end-stage renal disease (ESRD) program, 1973 through 1997.
    Hull AR
    Semin Nephrol; 1997 May; 17(3):160-9. PubMed ID: 9165645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surviving change: Can the ESRD provisions in the SCHIP create a level playing field?
    Gardner AV
    Nephrol News Issues; 2007 Sep; 21(10):52-3. PubMed ID: 17918480
    [No Abstract]   [Full Text] [Related]  

  • 14. Kidney Failure? Dialysis is the only medical service without automatic inflation updates from Medicare. Some people are trying to change that.
    Zigmond J
    Mod Healthc; 2006 Nov; 36(44):6-7, 14-6, 1. PubMed ID: 17128943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential impact of nutritional intervention on end-stage renal disease hospitalization, death, and treatment costs.
    Lacson E; Ikizler TA; Lazarus JM; Teng M; Hakim RM
    J Ren Nutr; 2007 Nov; 17(6):363-71. PubMed ID: 17971308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment modality patterns and transplantation among the United States pediatric end-stage renal disease population: a longitudinal study.
    Held PJ; Turenne MN; Liska DW; Zobel DL; Webb RL; Alexander SR; Jones C
    Clin Transpl; 1991; ():71-85. PubMed ID: 1820148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bundling and its potential impact on dialysis service providers.
    Sullivan J
    Nephrol News Issues; 2008 Oct; 22(11):12, 14, 16-7. PubMed ID: 19009855
    [No Abstract]   [Full Text] [Related]  

  • 18. Erythropoietin & ESRD payments: a promising policy outcome?
    Roe W
    Nephrol News Issues; 1989 Sep; 3(9):34-5. PubMed ID: 2682270
    [No Abstract]   [Full Text] [Related]  

  • 19. Palliative dialysis in end-stage renal disease.
    Trivedi DD
    Am J Hosp Palliat Care; 2011 Dec; 28(8):539-42. PubMed ID: 21398269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of initial dialysis modality and modality switches on Medicare expenditures of end-stage renal disease patients.
    Shih YC; Guo A; Just PM; Mujais S
    Kidney Int; 2005 Jul; 68(1):319-29. PubMed ID: 15954923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.